AbbVie announced that the SKYRIZI® subcutaneous administration induction treatment plan has been approved by the US Food and Drug Administration to treat adult patients with moderately to severely active Crohn's disease.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.